Salk scientists reveal role of genetic switch in pigmentation and melanoma
Despite only accounting for about 1 percent of skin cancers, melanoma causes the majority of skin cancer-related deaths. While treatments for this serious disease do exist, these drugs can vary in effectiveness depending on the individual. A study by Professor Marc Montminy and Staff Scientist Jelena Ostojić reveals new insights about a protein called CRTC3, a genetic switch that could potentially be targeted to develop new treatments for melanoma by keeping the switch turned off.
Featured Stories
The future starts upstreamFoundational discoveries are the source of tomorrow’s breakthroughs, but what happens if we let the river run dry?
Diana Hargreaves: Follow the ScienceThe BAF complex is near and dear to Diana Hargreaves, PhD, a scientist, professor, and the J.W. Kieckhefer Foundation Chair at Salk. Hargreaves was born in Atlanta, Georgia, to a physician-scientist mother, so science had a hold on her from the very beginning.
Ana Cabrera: Clearing the Path to DiscoveryCabrera is the senior director of strategic operations at Salk, a right-hand role to Chief Science Officer (CSO) Jan Karlseder, PhD. Cabrera and her colleagues in the CSO’s Office support Salk scientists through all of the logistical challenges that stand between them and their potential.
Aksinya Derevyanko: Finding strength in science, stage, and synapsesDerevyanko is a postdoctoral researcher training under Nicola Allen, PhD, a professor and neuroscientist at Salk.
